Trump’s Election Could Bring ‘Best Of Times’ For Pharma
Obama administration wasn’t bad but had ‘less than thrilling moments,’ BIO exec says; former FDA Commissioner says leadership, not scientific, skill is key attribute for next agency chief.
You may also be interested in...
Industry should act on drug pricing now while there is a post-election reprieve, Allergan CEO Brent Saunders said during the Forbes Healthcare Summit. Trump is a populist who will jump on the next big pricing scandal, he said.
From Newt Gingrich to President Barack Obama, speculation about who will be the central figures to watch in US health care policy in the Trump administration occupied panelists at the Partnering for Cures meeting.
A posting on the transition website takes a much milder tone than the GOP platform issued over the summer.